In the last 6 hours
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? The Motley Fool05:59
Yesterday
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients… AbbVie (Press Release)12:06 9-Dec-23
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High… Business Wire (Press Release)12:04 9-Dec-23
Hawaiian acquired by Alaska Air, AbbVie boasters portfolio: 4 big deal... Investing.com11:09 9-Dec-23
AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey;… ENDPOINTS06:09 9-Dec-23
Better Dividend Stock: AbbVie vs. Medical Properties Trust The Motley Fool05:16 9-Dec-23
In the last 7 days
AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio Investopedia15:29 8-Dec-23
AbbVie teams with Parkinson’s disease foundation for 'Flipping the Switch' effort ENDPOINTS15:05 8-Dec-23
AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodies PharmTech.com11:23 8-Dec-23
AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion PharmTech.com11:13 8-Dec-23
Thinking about trading options or stock in Taiwan Semiconductor, AbbVie, Shell PLC, HashiCorp,… PR Newswire (Press Release)09:32 8-Dec-23
AbbVie to tap Vraylar messaging lessons, but also create a new position to promote key… FiercePharma08:55 8-Dec-23
$19 Billion in a Week: AbbVie Makes Two Big Bets The Wall Street Journal07:02 8-Dec-23
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? The Motley Fool05:41 8-Dec-23
AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn European Pharmaceutical Review05:27 8-Dec-23
The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block Zacks05:06 8-Dec-23
AbbVie Says Buying Spree Will Add R&D Heft Needed For Long-Term Growth Scrip Pharma Intelligence18:18 7-Dec-23
Cerevel casts spell, charms Abbvie to $8.7B takeover BioWorld16:56 7-Dec-23
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals Benzinga15:30 7-Dec-23
Is AbbVie Making an $18.8 Billion Mistake? (Three Ways to Play It) Money Morning14:11 7-Dec-23
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say Reuters13:49 7-Dec-23
Cramer reacts to AbbVie buying Cerevel Therapeutics Invezz13:14 7-Dec-23
Dry Eye Disease Market to Register Immense Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading … GlobeNewswire (Press Release)13:05 7-Dec-23
AbbVie to Acquire Neuro Drugmaker Cerevel Therapeutics, for $8.7 Billion The Messenger12:22 7-Dec-23
Why Cerevel Therapeutics Stock Is Higher Benzinga12:15 7-Dec-23
AbbVie CEO Gonzalez brushes off FTC concerns for Cerevel buy: 'This acquisition is not… FierceBiotech11:38 7-Dec-23
Three big winners from AbbVie's $8.7B Cerevel deal: A drugmaker, a CEO and a SPAC ENDPOINTS11:19 7-Dec-23
AbbVie bets that nearly $20B in deals can bring it into the post-Humira future ENDPOINTS10:59 7-Dec-23
AbbVie acquiring Cerevel Therapeutics in $8.7B deal Yahoo! US10:24 7-Dec-23
AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B Proactive Investors (US)10:23 7-Dec-23
AbbVie purchases neuroscience developer Cerevel for $8.7B HealthLeaders10:20 7-Dec-23
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout Reuters09:56 7-Dec-23
AbbVie’s domination of top drug ad spenders continues, with overall spending holding high FiercePharma09:54 7-Dec-23
Palmoplantar Pustulosis Market to Grow significantly by 2032 | Kyowa Kirin Co., Ltd, Amgen,… Industry Today09:24 7-Dec-23
Still shopping, Abbvie takes over Cerevel for $8.7B BioWorld09:17 7-Dec-23
Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Benzinga08:01 7-Dec-23
Bain Capital-Backed Cerevel Therapeutics in $8bn Acquisition Talks with AbbVie Private Equity Insights07:45 7-Dec-23
AbbVie Continues Buying Spree with $8.7B Cerevel Acquisition to Bolster Neuro BioSpace07:26 7-Dec-23
AbbVie to expand neuroscience pipeline with $8.7bn Cerevel Therapeutics acquisition PMLiVE07:23 7-Dec-23
AbbVie Continues Buying Spree With $8.7 Billion Cerevel Deal (2) Bloomberg Law06:26 7-Dec-23
AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn Pharmafile06:25 7-Dec-23
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly? The Motley Fool05:56 7-Dec-23
AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion European Pharmaceutical Manufacturer05:48 7-Dec-23
AbbVie Does It Again With Fresh Pharma Acquisition Barron's Online05:41 7-Dec-23
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B Zacks05:09 7-Dec-23
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer pharmaphorum04:36 7-Dec-23
AbbVie to buy drug developer Cerevel for $8.7 billion RTE04:01 7-Dec-23
M & A News: AbbVie (NYSE:ABBV) Doubles Down on Acquisitions, Buys CERE for $8.7B TipRanks03:43 7-Dec-23
AbbVie agrees to acquire Cerevel Therapeutics for $8.7bn Pharmaceutical Technology03:42 7-Dec-23
AbbVie to Acquire Cerevel for $8.7B, Growing Neuro Drug Pipeline Genetic Engineering and Biotechnology News00:59 7-Dec-23
Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair… PR Newswire (Press Release)00:01 7-Dec-23
CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims… PR Newswire (Press Release)23:30 6-Dec-23
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics… Business Wire (Press Release)19:40 6-Dec-23
Kirkland-Led AbbVie To Pay $8.7B For Cerevel Therapeutics Law36019:16 6-Dec-23
AbbVie buying Cambridge biotech Cerevel for $8.7 billion Boston Globe18:33 6-Dec-23
AbbVie Strikes Again By Teeing Up $8.7bn Offer For Cerevel Scrip Pharma Intelligence18:32 6-Dec-23
AbbVie pads neuroscience portfolio with $8.7B deal to acquire Cerevel FierceBiotech17:41 6-Dec-23
AbbVie enters agreement to acquire Cerevel Therapeutics Investing.com17:33 6-Dec-23
AbbVie to buy Cerevel in $8.7B bet on brain drugs BioPharma Dive17:21 6-Dec-23
AbbVie to Buy Neuroscience Biotech Firm Cerevel for $8.7 Billion BNN Bloomberg17:16 6-Dec-23
Why Cerevel Therapeutics Holdings Is Moving After-Hours Benzinga17:16 6-Dec-23
STAT Plus: AbbVie purchases neuroscience developer Cerevel for $8.7 billion STAT17:11 6-Dec-23
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion CNBC17:11 6-Dec-23
Commentary: Targeted cancer drugs finally live up to the hype Channel NewsAsia17:10 6-Dec-23
AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal MarketWatch17:03 6-Dec-23
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion The Wall Street Journal16:54 6-Dec-23
Cerevel Therapeutics Shares Jump 14% on AbbVie Acquisition MarketWatch16:52 6-Dec-23
AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel ENDPOINTS16:52 6-Dec-23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline AbbVie (Press Release)16:32 6-Dec-23
AbbVie partners with BigHat to develop antibody therapies Pharmaceutical Technology10:01 6-Dec-23
Takeover in ADC space: Abbvie snags ImmunoGen European Biotechnology News03:59 6-Dec-23
Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028|… PR Newswire (Press Release)17:17 5-Dec-23
Decoding AbbVie's Options Activity: What's the Big Picture? Benzinga15:24 5-Dec-23
AbbVie’s new AI deal; Roche's PhIII win in breast cancer; SpringWorks to raise $275M ENDPOINTS11:21 5-Dec-23
Behcet’s Disease Market to grow significantly by 2032 | Amgen, Janssen Pharmaceutical,… Industry Today08:51 5-Dec-23
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning… AbbVie (Press Release)08:47 5-Dec-23
ABBV-400 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval Pharmaceutical Technology00:23 5-Dec-23
ABBV-514 by AbbVie for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2-… Pharmaceutical Technology00:23 5-Dec-23
ABBV-514 by AbbVie for Oral Cavity (Mouth) Cancer: Likelihood of Approval Pharmaceutical Technology00:23 5-Dec-23
ABBV-514 by AbbVie for Oropharyngeal Cancer: Likelihood of Approval Pharmaceutical Technology00:23 5-Dec-23
AbbVie agrees to acquire ImmunoGen for around $10.1bn Pharmaceutical Business Review06:01 4-Dec-23
AbbVie acquires biotech ImmunoGen Pharmaceutical Field04:51 4-Dec-23
AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition Seeking Alpha17:05 3-Dec-23
AbbVie Reports Third-Quarter 2023 Financial Results AbbVie (Press Release)07:45 3-Dec-23
In the last month
FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more ENDPOINTS06:03 2-Dec-23
AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time Seeking Alpha02:34 2-Dec-23
AbbVie: $10 Billion Cancer Deal To Boost Growth Seeking Alpha16:32 1-Dec-23
Immunogen's AbbVie Deal: Key Insights For Investors And Traders Seeking Alpha14:50 1-Dec-23
Pfizer, Idorsia and AbbVie drug brands lead the way in pharma digital marketing — study ENDPOINTS14:05 1-Dec-23
AbbVie will acquire antibody-drug conjugate specialist ImmunoGen for $10 billion Chemical & Engineering News13:43 1-Dec-23
AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio Investopedia12:33 1-Dec-23
J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey FiercePharma11:13 1-Dec-23
Over 6,000 women demand compensation for faulty breast implants in Amsterdam court NL Times10:45 1-Dec-23
AbbVie going big on ADCs through $10bn ImmunoGen buy BioProcess Insider10:09 1-Dec-23
AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval BioSpace09:40 1-Dec-23
Earnings call: CollPlant Biotechnologies Q3 2023 results highlight resilience amid conflict,… Investing.com09:21 1-Dec-23
AbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy Invezz09:06 1-Dec-23
AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition PMLiVE07:45 1-Dec-23
AbbVie buys ImmunoGen for $10.1 billion, expanding cancer drug portfolio Biopharma Reporter07:26 1-Dec-23
Sligo pharmaceutical firm named as one of Ireland’s great places to work The Sligo Champion07:08 1-Dec-23
AbbVie agrees $10 billion oncology acquisition European Pharmaceutical Review06:23 1-Dec-23
AbbVie to acquire ImmunoGen for approximately $10.1bn Pharmafile06:04 1-Dec-23
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion Zacks05:00 1-Dec-23
In brief: BioPharma Credit notes AbbVie takeover of investee ImmunoGen London South East04:54 1-Dec-23
Abbvie's $10bn swoop puts the spotlight on antibody-drug conjugates stocks Proactive Investors (US)03:41 1-Dec-23
AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker TipRanks21:57 30-Nov-23
Why Abbvie Stock Popped Today The Motley Fool19:27 30-Nov-23
AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space Scrip Pharma Intelligence18:29 30-Nov-23
AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology Seeking Alpha17:30 30-Nov-23
To engineer Elahere: Abbvie sees bright future in $10B Immunogen takeover BioWorld16:40 30-Nov-23
AbbVie to acquire ImmunoGen in $10B deal Yahoo! US16:15 30-Nov-23
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE… AbbVie (Press Release)15:45 30-Nov-23
ImmunoGen stock nearly doubled on Thursday: what happened? Invezz15:42 30-Nov-23
AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained Seeking Alpha15:16 30-Nov-23
Abbvie scooping up ADC player Immunogen in $10B pact BioWorld13:49 30-Nov-23

      
            
      
    view more headlines
   
      
      
      
10 Dec 05:59
   
AbbVie News

NewsNow aims to be the world's most accurate and comprehensive aggregator of AbbVie news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.
AbbVie

Latest News

AbbVie News

Pharmaceuticals Top Stories

Business Top Stories
